3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Basal Cell
3
Barrett Esophagus
2
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Nephrolithiasis
1
Multicystic renal dysplasia, bilateral
1
Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Hematuria
1
Esophageal Neoplasms
1
Carcinoma, Squamous Cell
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Benign Neoplasm of Liver and/or Biliary Ducts
1
Interventions
Cisplatin
90
Fluorouracil
76
Radiotherapy
63
Paclitaxel
58
Docetaxel
49
Oxaliplatin
48
Irinotecan
42
Leucovorin
32
Capecitabine
31
Carboplatin
27
Radiation
21
Surgical Procedures, Operative
20
Esophagectomy
20
pembrolizumab
15
Neoadjuvant Therapy
15
Bevacizumab
15
Cetuximab
13
Drug Therapy
12
Epirubicin
11
Chemotherapy, Adjuvant
9
S 1 (combination)
8
Magnetic Resonance Spectroscopy
8
Gemcitabine
8
Trastuzumab
7
Nivolumab
7
Erlotinib Hydrochloride
7
Surveys and Questionnaires
6
Panitumumab
6
Immunohistochemistry
6
Chemoradiotherapy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Esophageal Neoplasms
×
Microscopy, Confocal
×
Clear all
NCT01124214
2023-05-17
CEBE
Johns Hopkins University
Phase NA
Completed
68 enrolled